The use of TLR7 agonists without additional delivery of DCs to the tumor was also investigated in a murine breast cancer model, showing that TLR7-triggering on infiltrating plasmacytoid DCs resulted in their activation. The gene discussed is TLR7; the disease is breast carcinoma.